Cargando…
Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
BACKGROUND: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine outside the US), 10 mg twice daily, was approved by the US Food and Drug Administration (FDA) in January 2010 to improve walking in people with multiple sclerosis, as determine...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687626/ https://www.ncbi.nlm.nih.gov/pubmed/26719727 http://dx.doi.org/10.2147/DHPS.S97113 |